Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This study was a single-arm multicenter prospective phase II clinical study, designed to
evaluate the efficacy and safety of neoadjuvant nab-paclitaxel combined with S-1 in patients
with borderline resectable pancreatic cancer. A total of 60 subjects who meet the criteria
will receive neoadjuvant chemotherapy of nab-paclitaxel and S-1, for a maximum of 4 cycles
prior to pancreatectomy. The primary endpoint is R0 resection rate, the secondary endpoints
include overall survival and response rate.